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Michael F. Berger1,2* and Eliezer M. Van Allen3,4*The emerging paradigm of precision cancer medicine,
in which the use of molecular data at the point of care
directly impacts patient treatment and clinical decision-
making, has already had a substantial, direct clinical
impact on many aspects of medical oncology. Advances
in precision cancer medicine include well-established
molecularly targeted therapies for patients with BRAF-
mutant metastatic melanoma [1], those with EGFR-mu-
tant [2] or ALK-mutant [3] non-small-cell lung cancer,
and those with BCR–ABL-translocation-positive chronic
myelogenous leukemia [4]. In addition, the introduction
of large-scale genomic technologies at the point of care
[5–7] has catalyzed discoveries in translational oncology
and is driving new research that aims to dissect selective
responses to targeted, immune-driven therapies and to
chemotherapies, as well as identifying novel targets for
which therapies are now in development. Indeed, pro-
pelled by the ability to generate increasingly complex mo-
lecular data directly from patient tumor and germ-line
samples, the cycle of translating discoveries into clinical
practice may be accelerating.
However, precision cancer medicine remains a prom-
ise rather than a solid and robust reality in many areas
of clinical oncology. Molecular profiling of tumors is not
yet broadly applied in all types of cancer. Furthermore,
although the molecular landscapes of many cancers have
been revealed using precision oncology approaches,
many of the alterations observed in patients remain
undruggable, and viable targets are incompletely charac-
terized. In addition, a considerable amount of diversity
exists regarding the types of molecular tests being of-
fered clinically [8]; combined with the knowledge gap re-
garding the interpretation of genomic test results within
the field of clinical oncology, this diversity has fostered
confusion among physicians about the meaning and the* Correspondence: bergerm1@mskcc.org; evanallen@partners.org
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Perhaps most critically, prospective trials of molecular
profiling across cancers in an unselected manner are not
yet mature. In aggregate, these issues have limited the
practical applicability of precision cancer medicine, but
they also define the areas in which investment is needed
to make it a reality.
In this special issue of Genome Medicine, original re-
search and reviews from leaders in the field tackle the
current challenges in precision oncology. This special
issue details technological and analytical advances in
tumor characterization, which have provided novel in-
sights into the cancer genome and epigenome. In
addition, reports herein explore the integration of mo-
lecular profiling into clinical oncology to enable careful
assessment of the extent to which prospective clinical
sequencing is influencing treatment decisions and im-
proving outcomes, for both adult and pediatric can-
cers. Furthermore, as new targets are discovered and
novel drug resistance mechanisms emerge, combin-
ation therapies may prove to be advantageous, and
promising therapeutic strategies in immuno-oncology
will require new paradigms beyond the assignment of
molecularly targeted therapies that are based on a sin-
gle target lesion [10]. Improved methods to interpret
genomic variants and integrate genomic data into the
electronic health record [11] are essential for extend-
ing effective treatment options to patients who are
most likely to benefit. In addressing all of these topics,
this special issue provides a wide view of the current
state of the field and highlights the breadth of transla-
tional and clinical advances enabled by the application
of genomic approaches to the characterization, diagno-
sis, and treatment of cancer.
To capitalize on these advances and ensure maximal
benefit to patients, we advocate expanded access to
genomic testing for patients with all types of cancer.
Currently, reimbursement for tumor molecular profiling
is mostly limited to a small number of tumor types such
as lung cancer and melanoma, for which standard-of-
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dividual targetable alterations may occur across a wide
range of histologically defined tumor types and that the
same drug may elicit responses across different cancers.
Furthermore, broadening the application of molecular
profiling will be necessary to establish the evidence
base for genomically guided therapy for patients with
rare cancers and for patients with common cancers that
have rare mutations. Innovative clinical trials such as
“basket studies” [12], which enroll patients on the basis
of a specific genomic alteration that is shared across
many histologies, are essential for increasing access to
promising therapies and for evaluating the degree to
which drug response is determined by disease context.
Large academic medical centers have primarily funded
large-scale clinical sequencing through philanthropic
and research funds. This trend is unsustainable and it is
incumbent upon all stakeholders to ensure that tumor
genomic profiling is made available to all who might
benefit from it.
With expanded access to genomic profiling, obtaining
the necessary data regarding treatment outcomes and car-
rying out prospective randomized controlled trials may
become more feasible at the scale necessary to determine
the clinical impact of this approach across cancer types,
given the clinically heterogeneous patient populations that
would receive such testing. In addition, this approach will
highlight areas in which current methodology is insuffi-
cient and in which other profiling approaches, such as
transcriptome or epigenetic profiling, may provide further
clinical impact. Towards that end, studies in prostate [13]
and pediatric [14] cancers have already indicated the bene-
fit of adding transcriptome-level data to genome-level data
to identify actionable targets. Such an approach may also
inform multi-omic features that are associated with re-
sponse and resistance to emerging immuno-oncology
treatment paradigms, which may foster new methods for
patient stratification and highlight resistance mechanisms
that, in turn, may identify novel combination strategies.
Finally, a complete assessment of the utility of genomic
profiling in clinical oncology will require genomic and
clinical data to be shared across institutions. Data-sharing
is a central tenet of the Cancer Moonshot initiative [15]
advocated by Vice President Biden, and the National
Cancer Institute recently launched the Genomic Data
Commons to centralize and standardize cancer genomic
data [16]. Given the rarity of many putative targetable
mutations in cancer, data-sharing among institutions
and clinical laboratories engaged in tumor sequencing
is necessary to prioritize novel biomarkers that may
inform future treatment decisions. Furthermore, data-
sharing driven by cancer patients themselves may comple-
ment these approaches through patients’ right of access to
medical records. Integrating data generated by multipleplatforms and modalities may enable the identification
of novel genetic targets that would go undetected if the
data remain in silos. Ultimately, these steps are neces-
sary to build on the efforts described in this special
issue and to bring us closer to truly delivering on the
promise of precision medicine in cancer.
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